Patents Assigned to Alcon
  • PYRANOINDAZOLE CYCLIC CARBONATES AND METHODS OF USE
    Publication number: 20080058533
    Abstract: Described are methods of making pyranoindazole compounds comprising converting a pyranoindazole diol mixture to form a diastereomeric mixture of cyclic pyranoindazole carbonates, separating the mixture of cyclic pyranoindazole carbonates, and converting at least one of the separated diastereoisomeric cyclic pyranoindazole carbonates by hydrogenolysis. Also disclosed are intermediates useful for such and additional methods.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 6, 2008
    Applicant: ALCON, INC.
    Inventors: Pete DELGADO, Raymond CONROW
  • ANTAGONISTS OF CI-M6P/IGF2R FOR PREVENTION AND TREATMENT OF CTGF-MEDIATED OCULAR DISORDERS
    Publication number: 20080057072
    Abstract: Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 6, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Allan R. SHEPARD, Debra L. FLEENOR, Abbot F. CLARK, Najam A. SHARIF
  • Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
    Patent number: 7338972
    Abstract: Substituted 1-alkylamino-1H-indazoles for lowering intraocular pressure and treating glaucoma are disclosed.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: March 4, 2008
    Assignee: Alcon, Inc.
    Inventors: Anura P. Dantanarayana, Jesse A. May
  • RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS
    Publication number: 20080051361
    Abstract: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: August 24, 2007
    Publication date: February 28, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Jon Chatterton, Abbot Clark
  • Kit management system
    Patent number: 7331462
    Abstract: A kit management system for use in microsurgery is disclosed. The kit management system includes a plurality of tubing, surgical instruments, connectors, an instrument tray, a connector tray, and a tubing organizer. A tubing organizer for removably receiving and holding a plurality of tubing in a spaced relationship during microsurgery is also disclosed.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: February 19, 2008
    Assignee: Alcon, Inc.
    Inventor: Dennis L. Steppe
  • Ophthalmic compositions containing a synergistic combination of three polymers
    Patent number: 7329411
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: February 12, 2008
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • PROCESS FOR PREPARING PYRANOINDAZOLE SEROTONERGIC RECEPTOR AGONISTS
    Publication number: 20080033183
    Abstract: Described are methods of making pyranoindazoles comprising reacting with a reducing agent a protected halohydrin comprising a secondary carbamate to form a pyranoindazole. In preferred embodiments the secondary carbamate is a benzyl carbamate. Also preferred are embodiments wherein the reacting is preceded by reacting a protected halohydrin with a first organometallic compound. The pyranoindazoles thus formed by the described methods are preferably pharmaceutically active products.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 7, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventor: Raymond E. CONROW
  • INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS
    Publication number: 20080033184
    Abstract: Disclosed is a method of making a 1-alkylindazole comprising reacting a 1-acylindazole with a first reducing agent, and contacting the resulting mixture with an acid anhydride or acyl halide, and with pyridine or a 4-dialkylaminopyridine or a combination of pyridine and a 4-dialkylaminopyridine, to form a hemiaminal ester and reacting the hemiaminal ester with a second reducing agent to form a 1-alkylindazole. Also disclosed are intermediates for the synthesis of 1-alkylindazoles.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 7, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Pete Delgado, W. Dennis Dean, Raymond E. Conrow
  • Intraocular pressure control
    Patent number: 7326183
    Abstract: An improved method of controlling intraocular pressure with a microsurgical system using measured flow rate and a dual infusion chamber.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: February 5, 2008
    Assignee: Alcon, Inc.
    Inventors: Nader Nazarifar, Frederick Reed, John C. Huculak, Roger Thomas
  • ANTAGONISTS OF ENDOTHELIAL DIFFERENTIATION GENE SUBFAMILY 3 (EDG-3, S1P3) RECEPTORS FOR PREVENTION AND TREATMENT OF OCULAR DISORDERS
    Publication number: 20080025973
    Abstract: Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 31, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Debra L. FLEENOR, Allan R. SHEPARD, Iok-Hou PANG
  • Intraocular Irrigating Solution Having Improved Flow Characteristics
    Publication number: 20080020017
    Abstract: Improved intraocular irrigating solutions are described. The solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles. The solutions preferably also have modified surface tensions that more closely resemble the surface tension of the aqueous humor.
    Type: Application
    Filed: October 4, 2007
    Publication date: January 24, 2008
    Applicant: ALCON, INC.
    Inventors: Mandar Shah, Mikhail Boukhny, William Garner, Kerry Markwardt, Uday Doshi
  • LOW-TACK OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS
    Publication number: 20080021129
    Abstract: Disclosed are soft, high refractive index, acrylic materials. These materials, especially useful as intraocular lens materials, contain an aryl acrylic hydrophobic monomer as the single principal device-forming monomer and a tack-reducing macromer additive. In addition to their use as intraocular lens materials, the present materials are also suitable for use in other ophthalmic or otorhinolaryngological devices, such as contact lenses, keratoprostheses, corneal inlays or rings; otological ventilation tubes and nasal implants.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: Diana M. Cordova, Mutlu Karakelle, Chance Lehman, Douglas C. Schlueter, Joseph I. Weinschenk
  • LOW-TACK OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS
    Publication number: 20080021548
    Abstract: Disclosed are soft, high refractive index, acrylic materials. These materials, especially useful as intraocular lens materials, contain an aryl acrylic hydrophobic monomer as the single principal device-forming monomer and a tack-reducing macromer additive. In addition to their use as intraocular lens materials, the present materials are also suitable for use in other ophthalmic or otorhinolaryngological devices, such as contact lenses, keratoprostheses, corneal inlays or rings; otological ventilation tubes and nasal implants.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: Diana M. Cordova, Mutlu Karakelle, Chance Lehman, Douglas C. Schlueter, Joseph I. Weinschenk
  • Accommodative intraocular lens system
    Patent number: 7316713
    Abstract: A two optic accommodative lens system. The present invention also contemplates the use of a cam mechanism to adjust the distance power via adjustment of the dual lens separation when the eye is at distance vision stasis. The cam mechanism allows for distance/base power adjustment as needed.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: January 8, 2008
    Assignee: Alcon, Inc.
    Inventor: Xiaoxiao Zhang
  • HISTONE DEACETYLASE INHIBITORS FOR TREATING DEGENERATIVE DISEASES OF THE EYE
    Publication number: 20080004311
    Abstract: Compositions and methods for treating degenerative conditions and diseases of the eye with histone deacetylase inhibitors are disclosed.
    Type: Application
    Filed: August 9, 2007
    Publication date: January 3, 2008
    Applicant: ALCON, INC.
    Inventor: Peggy Hellberg
  • ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA
    Publication number: 20070293475
    Abstract: Aryl tetrahydrobenzazepine derivatives with minimal 5-HT2B activity relative to 5-HT2A and 5-HT2C activity that are useful for treating glaucoma are disclosed.
    Type: Application
    Filed: June 12, 2007
    Publication date: December 20, 2007
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: Suchismita Mohapatra, Mark R. Hellberg, Zixia Feng
  • Ophthalmic compositions containing a synergistic combination of three polymers
    Patent number: 7306802
    Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: December 11, 2007
    Assignee: Alcon, Inc.
    Inventors: Masood A. Chowhan, Huagang Chen
  • RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20070281901
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: May 17, 2007
    Publication date: December 6, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: John Yanni, Jon Chatterton, Diane Senchyna, Daniel Gamache, Steven Miller
  • RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20070275922
    Abstract: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 29, 2006
    Publication date: November 29, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, David Bingaman
  • Intraocular lens
    Patent number: 7300464
    Abstract: A two or three component lens system. The first component is a ring-like supporting component that is implanted in the capsular bag following cataract surgery. The first component is a non-optical component and does not correct for any refractive errors. The first component may contains features to help reduce or eliminate PCO. The second component is an optical component that may contain all of the corrective optical power of the lens system. The second component has a pair of tabs for locking the second component within the first component. The third component is optional and is similar to second component and contains some optical power to correct for any residual optical error not corrected by the second component. The second and third components may also be implanted so as to move relative to one another, thereby providing some accommodation.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: November 27, 2007
    Assignee: Alcon, Inc.
    Inventor: Son Trung Tran